Combination therapy for patients with uncontrolled type 2 diabetes mellitus: Adding empagliflozin to pioglitazone or pioglitazone plus metformin

Expert Opinion on Drug Safety

Volumn 14, Issue 5, 2015, Pages 789-793

  Blevins, Thomas ^a  

^a Texas Diabetes and Endocrinology   (United States)

Author keywords

Combination therapy; Empagliflozin; Metformin; Phase III clinical trial; Pioglitazone; SGLT2 inhibitors; Type 2 diabetes mellitus

Indexed keywords

EMPAGLIFLOZIN; HEMOGLOBIN A1C; METFORMIN PLUS PIOGLITAZONE; PIOGLITAZONE; PLACEBO; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE; METFORMIN; SODIUM GLUCOSE COTRANSPORTER 2;

ADD ON THERAPY; CLINICAL PRACTICE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; KIDNEY FUNCTION; MONOTHERAPY; MULTICENTER STUDY (TOPIC); MYCOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; URINARY TRACT INFECTION; ANTAGONISTS AND INHIBITORS; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; FEMALE; MALE; WEIGHT REDUCTION;

BENZHYDRYL COMPOUNDS; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; SODIUM-GLUCOSE TRANSPORTER 2; THIAZOLIDINEDIONES; WEIGHT LOSS;

EID: 84928317576     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2015.1020294     Document Type: Review

References (11)

1. Kovacs CS, Seshiah V, Swallow R, et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab 2014;16:147-58
2. Neumiller JJ. Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. Drugs Context 2014;3:212262
3. Liakos A, Karagiannis T, Athanasiadou E, et al. Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 2014;16:984-93
4. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140-9
5. Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE comprehensive diabetes management algorithm 2013. Endocr Pract 2013;19:327-36
6. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2015;38(Suppl):S1-93
7. Roden M, Weng J, Eilbracht J, et al. EMPA-REG MONO trial investigators. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 2013;1:208-19
8. Häring HU, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2014;37:1650-9
9. Boehringer Ingelheim Pharmaceuticals, Inc. Jardiance (empagliflozin) [prescribing information]. 2014. Available from: https://www.jardiance.com [Last accessed 15 December 2014]
10. Ridderstrale M, Andersen KR, Zeller C, et al. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double blind, phase 3 trial. Lancet Diabetes Endocrinol 2014;2:691-700
11. Oliva RV, Bakris GL. Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens 2014;8:330-9